6 news items
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
ATNM
KURA
SLS
18 Jun 24
activity, safety and tolerability of ziftomenib in patients with R/R NPM1-mutant AML, with a primary endpoint of complete response. The study has completed
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
SYRS
13 Jun 24
trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
by our belief that tamibarotene has a differentiated safety profile well suited for use in these patients
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
of venetoclax and azacitidine was generally well tolerated, and the overall safety profile demonstrated no additive toxicities or new safety signals
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
SYRS
27 Mar 24
clinical experience, tamibarotene in combination with approved doses of venetoclax and azacitidine was generally well tolerated, and the overall safety
58u5mc 6e2rag4
SYRS
25 Mar 24
in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its
- Prev
- 1
- Next